Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives: Interactions with tubulin

Biochemical Pharmacology

Volumn 51, Issue 1, 1996, Pages 53-59

  Hamel, Ernest ^a   Lin, Chii M ^a   Plowman, Jacqueline ^b   Wang, Hui Kang ^c   Lee, Kuo Hsiung ^c   Paull, Kenneth D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antimitotic agents; Colchicine analogs; Flavonols; Phenylquinolone derivative; Styrylquinazolinone derivatives; Tubulin polymerization

Indexed keywords

2 PHENYL 4 QUINOLONE DERIVATIVE; 2 STYRYLQUINAZOLIN 4(3H) ONE DERIVATIVE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; COLCHICINE; COLCHICINE DERIVATIVE; CS A4; DEOXYPODOPHYLOTOXIN; DOLASTATIN 10; FLAVONOL DERIVATIVE; HALICHONDRIN B; MAYTANSINE; NOCODAZOLE; PELTATIN A; PODOPHYLOTOXIN; QUINAZOLINONE DERIVATIVE; RADIOISOTOPE; RHIZOXIN; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN; CANCER CELL CULTURE; CATTLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG MECHANISM; DRUG SCREENING; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA L 1210; LEUKEMIA P 388; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BRAIN; CATTLE; CELL DIVISION; COLCHICINE; GROWTH INHIBITORS; LEUKEMIA, EXPERIMENTAL; MICE; PODOPHYLLOTOXIN; PROTEIN BINDING; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; STYRENES; TUBULIN; VINBLASTINE;

EID: 0030048231     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02156-6     Document Type: Article

References (24)

1. Yale HL and Kalkstein M, Substituted 2,3-dihydro-4-(1H)-quinazolinones. A new class of inhibitors of cell multiplication. J Med Chem 10: 334-336, 1967.
2. Neil GL, Li LH, Buskirk HH and Moxley TE, Antitumor effects of the antispermatogenic agent, 2,3-dihydro-2-(1-naphthyl)-4(1H)-quinazolinone (NSC-145669). Cancer Chemother Rep 56: 163-173, 1972.
3. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M, Feasibility of a high-flux anticancer drug screen utilizing a diverse panel of human tumor cell lines in culture. J Natl Cancer Inst 83: 757-766, 1991.
4. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR, Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092, 1989.
5. Paull KD, Hamel E and Malspeis L, Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: Cancer Chemotherapeutic Agents (Ed. Foye WO), pp. 9-45. American Chemical Society, Washington, DC, 1995.
6. Paull KD, Lin CM, Malspeis L and Hamel E, Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52: 3892-3900, 1992.
7. Jiang JB, Hesson DP, Dusak BA, Dexter DL, Kang GJ and Hamel E, Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. J Med Chem 33: 1721-1728, 1990.
8. Lin CM, Kang GJ, Roach MC, Jiang JB, Hesson DP, Luduena RF and Hamel E, Investigation of the mechanism of the interaction of tubulin with derivatives of 2-styrylquinazolin-4(3H)-one. Mol Pharmacol 40: 827-832, 1991.
9. Kuo S-C, Lee H-Z, Juang J-P, Lin Y-T, Wu T-S, Chang J-J, Lednicer D, Paull KD, Lin CM, Hamel E and Lee K-H, Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4′-substituted phenyl)-4-quinolones and related compounds: Identification as antimitotic agents interacting with tubulin. J Med Chem 36: 1146-1156, 1993.
10. Li L, Wang H-K, Kuo S-C, Wu T-S, Lednicer D, Lin CM, Hamel E and Lee K-H, 2′,3′,4′,5′,5,6,7-Substituted 2-phenyl-4-quinolones and related compounds: Their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem 37: 1126-1135, 1994.
11. Li L, Wang H-K, Kuo S-C, Wu T-S, Mauger A, Lin CM, Hamel E and Lee K-H, Synthesis and biological evaluation of 3′,6,7-substituted 2-phenyl-4-quinolones as antimitotic antitumor agents. J Med Chem 37: 3400-3407, 1994.
12. Beutler JA, Cardellina JH II, Lin CM, Hamel E, Cragg GM and Boyd MR, Centaureidin, a cytotoxic flavone from Polymnia fruticosa inhibits tubulin polymerization. Bioorg Med Chem Lett 3: 581-584, 1993.
13. Shi Q, Chen K, Li L, Chang J-J, Autry C, Kozuka M, Konoshima T, Estes JR, Lin CM, Hamel E, McPhail AT, McPhail DR and Lee K-H, Cytotoxic and antimitotic flavonols from Polonisia dodecandra. J Nat Prod 58: 475-482, 1995.
14. Lichius JJ, Thoison O, Montagnac A, Païs M, Guéritte-Voegelein F and Sévenet T, Antimitotic and cytotoxic flavonols from Zieridium pseudobtusifolium and Acronychia porteri. J Nat Prod 57: 1012-1016, 1994.
15. Hamel E and Lin CM, Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry 23: 4173-4184, 1984.
16. Kang G-J, Getahun Z, Muzaffar A, Brossi A and Hamel E, N-Acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring: Evaluation of the mechanistic basis for their enhanced biological properties. J Biol Chem 265: 10255-10259, 1990.
17. Hamel E and Lin CM, Stabilization of the colchicine-binding activity of tubulin by organic acids. Biochim Biophys Acta 675: 226-231, 1981.
18. Bai R, Pettit GR and Hamel E, Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941-1949, 1990.
19. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM and Abbott BJ, Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep (Part 3) 3(2): 1-103, 1972.
20. Blokhin AV, Yoo H-D, Geralds RS, Nagle DG, Gerwick WH and Hamel E, Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogs. Mol Pharmacol 48: 523-531, 1995.
21. Medarde M, de Clairac RP-L, Ramos AC, Caballero E, López JL, Grávalos DG and San Feliciano A, Synthesis and pharmacological activity of combretastatin analogues. Naphthylcombretastatins and related compounds. Bioorg Med Chem Lett 5: 229-232, 1995.
22. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR and Hamel E, Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Mol Pharmacol 34: 200-208, 1988.
23. Brossi A, Yeh HJC, Chrzanowska M, Wolff J, Hamel E, Lin CM, Quinn F, Suffness M and Silverton J, Colchicine and its analogues: Recent findings. Med Res Rev 8: 77-94, 1988.
24. Cushman M, Nagarathnam D, Gopal D, He H-M, Lin CM and Hamel E, Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem 35: 2293-2306, 1992.